Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire
Viiv's Dovato as Effective as Gilead' Biktarvy for HIV but With Less Weight Gain
Gilead Sciences (GILD) Receives a Buy From TD Cowen
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
Gilead Sciences: A Balanced Outlook With Steady HIV Performance and Oncology Challenges Justifying a Hold Rating
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)
Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Gilead Sciences Is Maintained at Neutral by Cantor Fitzgerald
Gilead Sciences Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75
AHF Press Conference: Advocates Demand Gilead to Put Lives Before Profits at AIDS 2024
Here Are Big Pharma's Leading Blockbuster Makers
Gilead Sciences' (NASDAQ:GILD) One-year Decline in Earnings Translates Into Losses for Shareholders
Check Out What Whales Are Doing With GILD
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Raises Target Price to $85
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)